

# Study group – Lung Tumors


Oligometastatic disease of the lung presents us with an increasing challenge. To date, it is not fully understood what limited metastasis really includes. In order to examine this, the interdisciplinary lung tumor study group (consists of radiotherapists, thoracic surgeons, pulmonologists, and medical oncologists of the BZKF) is conducting a joint retrospective analysis of its patients, which will now lead to a prospective study. In parallel, a platform for industry studies was established: The BZKF study platform for lung cancer.

**Speaker:** Prof. Dr. Christian Schulz, Regensburg

## Concepts

## Achievements (Milestones 1<sup>st</sup> FP)


### Retrospective OMD cohort



Retrospective analysis ongoing

- ✓ Patients from several disciplines (radiotherapy, thoracic surgery, pulmonology, and medical oncology) were collected and the data will be analysed in the near future (n=398 patients).
- ✓ Already 4 of 6 BZKF sites participated in the collection.


### Prospective OMD cohort with biomarker sampling



Successful completion of regulatory affairs

- ✓ Joint ethics committee approval
- ✓ Informed consent form prepared and approved
- ✓ Laboratory manuals finalized
- ✓ Official initiation not yet conducted

### Establishment of a BZKF study platform for lung cancer



Bundling Expertise to Accelerate Trial Set-up

- ✓ Close collaboration of the ECTU trial coordinators allowing a rapid set-up of early phase clinical trials in immuno-oncology and personalized oncology programs
- ✓ Drug master screening study for a trial for patients with locally advanced, unresectable stage III NSCLC

## Work plan (Milestones 2<sup>nd</sup> FP)

- » Start of the prospective OMD cohort and measurement of the already collected biosamples
- » Set-up and initiation of the second industry study for SCLC with a theranostic therapeutic
- » Protocol development of a further IIT on the basis of the BZKF study platform for lung cancer (first discussions about a possible protocol and financing is already ongoing).

**Authors:** **UKA:** Björn Hackanson, Stephan Raab; **UKE:** Florian Fuchs, Kai Hildner; **LMU:** Amanda Tufman, Farkhad Manapov; **TUM:** Hans Hoffmann, Denise Bernhardt; **UKR:** Christian Schulz, Daniel Heudobler; **UKW:** Philip Kleine, Maria-Elisabeth Goebeler.

